Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Change in Receivables (2016 - 2025)

Phibro Animal Health (PAHC) has 13 years of Change in Receivables data on record, last reported at -$2.3 million in Q4 2025.

  • For Q4 2025, Change in Receivables fell 106.67% year-over-year to -$2.3 million; the TTM value through Dec 2025 reached $15.7 million, down 67.75%, while the annual FY2025 figure was $55.2 million, 536.18% up from the prior year.
  • Change in Receivables reached -$2.3 million in Q4 2025 per PAHC's latest filing, up from -$11.4 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $35.0 million in Q4 2024 and bottomed at -$22.3 million in Q3 2022.
  • Average Change in Receivables over 5 years is $4.5 million, with a median of $5.5 million recorded in 2022.
  • Peak YoY movement for Change in Receivables: plummeted 411.02% in 2022, then surged 7819.86% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $2.9 million in 2021, then soared by 154.85% to $7.5 million in 2022, then tumbled by 120.44% to -$1.5 million in 2023, then surged by 2379.41% to $35.0 million in 2024, then crashed by 106.67% to -$2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$2.3 million in Q4 2025, -$11.4 million in Q3 2025, and $26.0 million in Q2 2025.